Session » (1467–1516) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II

Date: Monday, October 27, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 1468

A HIPAA-Compliant LLM for Personalized Therapeutic Decision-Making in Lupus Nephritis

10:30AM-12:30PM: Abstract Number: 1497

Acute Care Utilization in Patients with Antiphospholipid Syndrome and/or Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 1512

Anti-U1-RNP Antibody Positivity is Associated with Elevated Interferon Score in SLE Irrespective of Disease Activity: A Transcriptome Analysis in Japanese Patients

10:30AM-12:30PM: Abstract Number: 1476

Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus: A Meta-Analysis of Prevalence and Clinical Correlates

10:30AM-12:30PM: Abstract Number: 1510

Biomarker landscape for neuropsychiatric involvement in patient with systemic lupus erythematosus

10:30AM-12:30PM: Abstract Number: 1498

Both Race and Socioeconomic Status Affect Mortality in SLE

10:30AM-12:30PM: Abstract Number: 1477

Can Large Language Models Support Clinical Decision-Making in Atypical SLE? A Comparative Analysis

10:30AM-12:30PM: Abstract Number: 1472

Characteristics and Predictors of LLDAS in Survivors of Early Active Lupus: Insights from a Decade-Long Cohort

10:30AM-12:30PM: Abstract Number: 1494

Comparing Childhood-Onset Versus Adult-Onset Systemic Lupus Erythematosus Young Adults’ Lived Employment Experiences

10:30AM-12:30PM: Abstract Number: 1495

Comparing the 0-10 Physician Global Assessment Scale to Categorical Disease Activity States among Pediatric Patients with SLE

10:30AM-12:30PM: Abstract Number: 1473

Comparison of Three Different Double-Stranded DNA Antibody Assays in the Diagnosis of Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 1478

Construction and Validation of a Prediction Model of Cognitive Dysfunction in Patients with Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 1484

Decoding the Impact of Systemic Lupus Erythematosus on Transcatheter Aortic Valve Implantation: A Nationwide population-based Study

10:30AM-12:30PM: Abstract Number: 1496

Demyelinating Syndromes in Systemic Lupus Erythematosus: A 23-Year Retrospective Analysis of Clinical Features and Treatment Outcomes from a Tertiary Care Center

10:30AM-12:30PM: Abstract Number: 1505

Discordance Between Physician and Patient Global Assessment of Disease Activity in a Large Multicenter Prospective SLE Cohort in the U.S. and Canada

10:30AM-12:30PM: Abstract Number: 1508

Dissecting the Role of T Cell Subsets and Complements in Lupus Pathogenesis in Systemic Lupus Erythematosus Patients with Obesity

10:30AM-12:30PM: Abstract Number: 1481

Duffy Antigen Screening in Systemic Lupus Erythematosus Patients with Neutropenia: A Quality Improvement Initiative

10:30AM-12:30PM: Abstract Number: 1482

Evaluation of T Cell Subpopulations, CD4/CD8 Ratio and p16INK4a in Patients with Systemic Lupus Erythematosus and Cognitive Impairment

10:30AM-12:30PM: Abstract Number: 1483

Evidence of Early Cardiovascular Dysfunction in Young Systemic Lupus Erythematosus Patients Compared to Older Healthy Controls

10:30AM-12:30PM: Abstract Number: 1491

Feasibility of Extrarenal Systemic Lupus Erythematosus Disease Modification in GLADEL 2.0, a Latin American Cohort

10:30AM-12:30PM: Abstract Number: 1504

High prevalence of clonal hematopoiesis of indeterminate potential (CHIP) somatic mutations in a cohort of 1,073 SLE participants

10:30AM-12:30PM: Abstract Number: 1475

Humoral immune responses to real-world recombinant zoster vaccination in systemic lupus erythematosus

10:30AM-12:30PM: Abstract Number: 1489

Impact of Menopause on Long-Term Outcomes in Patients with Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 1488

Limited Concordance Between anti-dsDNA Assays and Association with Lupus Nephritis

10:30AM-12:30PM: Abstract Number: 1493

Long-Term Outcomes in Systemic Lupus Erythematosus Patients Infected with SARS-CoV-2: Variant-Specific Analysis of Pre-Delta/Delta and Omicron Periods

10:30AM-12:30PM: Abstract Number: 1503

Lupus Disease Activity Adversely Affects the Quality of Life but not Intimate Relationship and Sexual Function in Indian Female Lupus Patients

10:30AM-12:30PM: Abstract Number: 1485

Lupus Under the Lens: Fibrinogen-to-Albumin Ratio as a Novel Inflammatory Index

10:30AM-12:30PM: Abstract Number: 1515

Machine Learning–Defined Subtypes of Systemic Lupus Erythematosus Identify Distinct Immunologic and Molecular Signatures

10:30AM-12:30PM: Abstract Number: 1511

Mental Health and Medical Burden: The Impact of Depression on Length of Stay in Lupus Patients

10:30AM-12:30PM: Abstract Number: 1509

Outcome of Newly Diagnosed SLE with Serositis and Its Clinical Features in Daily Clinical Practice: A Single Center Study

10:30AM-12:30PM: Abstract Number: 1506

Perspectives on Clinical Trial Participation for Novel Advanced Therapies: A Focus Group Study in Systemic Lupus Erythematosus (SLE)

10:30AM-12:30PM: Abstract Number: 1499

Predictors of Proteinuria Flares in Biopsy Positive Lupus Nephritis

10:30AM-12:30PM: Abstract Number: 1502

Prevalence and Associated Factors of Autoimmune Hepatitis and Primary Sclerosing Cholangitis in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis

10:30AM-12:30PM: Abstract Number: 1471

Prevalence and Clinical Outcomes of Hemophagocytic Lymphohistiocytosis in Systemic Lupus Erythematosus: A Multi-Institutional Cohort Study

10:30AM-12:30PM: Abstract Number: 1492

Prevalence and Risk Factors of Gynecologic Cancers in Female Patients with Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 1500

Prognostic Impact of Thrombocytopenia on Morbidity and Mortality in Systemic Lupus Erythematosus: A Retrospective Single-Center Study

10:30AM-12:30PM: Abstract Number: 1513

Race, Renal Failure, and Risk: A five-to-ten year retrospective cohort study of Racial differences in outcomes of patients with dialysis-dependent Lupus nephritis

10:30AM-12:30PM: Abstract Number: 1469

Remission, Low Level Disease Activity State (LLDAS) and Relapse in Patients With Early-Onset, Adult-Onset and Late-Onset Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 1474

Rethinking Heart Risk Prediction for Lupus Patients

10:30AM-12:30PM: Abstract Number: 1467

Risk Factors Associated with Chronic Kidney Disease and End-Stage Kidney Disease in Patients with Newly Diagnosed Lupus Nephritis

10:30AM-12:30PM: Abstract Number: 1514

Serum Antigenome Profiling Reveals Diagnostic Models for Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 1486

Systemic Lupus Erythematosus and Statins in GLADEL 2.0: Are Cardiovascular Risk Prevention Guidelines Being Followed?

10:30AM-12:30PM: Abstract Number: 1507

Temporal Trends in the Incidence of Systemic Lupus Erythematosus (SLE) in the United States (US): Holding Steady?

10:30AM-12:30PM: Abstract Number: 1516

The Benefits of SGLT2i on GFR Slope and Proteinuria in SLE Depend on Subgroups of Diabetes Mellitus and Baseline eGFR

10:30AM-12:30PM: Abstract Number: 1501

Thrombocytopenia in SLE: A Hidden Prognostic Marker of Increased Mortality and Adverse Outcomes – Results from Real World Data

10:30AM-12:30PM: Abstract Number: 1480

Urinary Biomarkers Detect Proliferative Lupus Nephritis in SLE Patients with Subclinical Proteinuria.

10:30AM-12:30PM: Abstract Number: 1479

Validation of Attention, Memory, and Frontal-Executive Abilities Screening Test (AMFAST) in Systemic Lupus Erythematosus (SLE), a prospective single-center study in The Bronx

10:30AM-12:30PM: Abstract Number: 1490

Vitamin D Deficiency and Its Relationship with Inflammatory Biomarkers in SLE: A Focus on Neutrophil-to-Lymphocyte Ratio

10:30AM-12:30PM: Abstract Number: 1487

Whole Health Empowerment for Endotypes of Lupus (WHEEL) Program: User Testing Findings on Feasibility, Acceptability, and Opportunities for Intervention Refinement

10:30AM-12:30PM: Abstract Number: 1470

Why Do Some Lupus Patients Skip Their Mycophenolate Mofetil? A Multi-Factorial Assessment of Patient Compliance

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].